Insys Therapeutics Stock Gave Us a 26% Return in Just 12 Days... and That's Only the Start

Insys Therapeutics StockInsys Therapeutics stock gave Money Morning readers nearly 26% gains in just 12 trading sessions after Money Morning Executive Editor Bill Patalon recommended buying the stock on May 15. He recommended the stock before the Food and Drug Administration (FDA) gave the company final approval for its new drug on May 24. And this approval is just the beginning of big profits with Insys Therapeutics Inc. (Nasdaq: INSY).

If you missed the gains last month, it's not too late to profit from Insys stock. Right now, we've been presented with another great buying point after "news" created unwarranted panic-selling in the last week.

On Sunday, June 4, Megyn Kelly aired a damaging story about a former Insys business practice where company officials bribed doctors to prescribe opioid pain killers. The story appeared on her new show "Sunday Night with Megyn Kelly."

But there was a massive problem with the story. The original news of the scandal actually broke on Nov. 6, 2015. Since then, the executives associated with the scandal have been fired. According to Patalon, the business has implemented operational checks to make sure something like that never happens again. (Click here for the full story if you already receive Patalon's Private Briefing.)

Editor's Note: Patalon's Private Briefing investment service has delivered 217 double- and triple-digit peak-gain winners since 2011. To learn how to get Patalon's research delivered straight to your inbox, click here ...

Unfortunately, most viewers didn't realize the news was old, and the panic-selling caused the stock to plunge 12% since the markets opened on Monday. Still, the stock is up 31% year to date, and this pullback has done nothing more than present us with a great buying opportunity for Insys Therapeutics stock...

Why We Still Like Insys Therapeutics Stock in 2017

The negative news this week has done nothing to dampen the company's prospects. On May 24, Insys cleared the last FDA hurtle to bring its drug Syndros to market.

Syndros is a cannabis-derived drug that treats nausea in chemotherapy patients and anorexia in AIDS patients.

The potential market for this drug is huge...

According to the National Cancer Institute, there were almost 15 million people with cancer in the United States in 2014. Of those patients, 80% suffer from chemotherapy-induced nausea and vomiting. This makes Syndros' potential market roughly 12 million patients.

This is in addition to the company's breakthrough pain spray, Subsys. Subsys is the only treatment FDA approved for breakthrough pain in cancer patients. Sales of the drug to Insys' four largest wholesale clients amounted to $22 million for Q1 of 2017. Another $11 million in sales of Subsys was made to specialty pharmaceutical retailers for the quarter.

Plus, Insys is working on six more treatments. Two are in phase 3 trials, while the remaining four are in phase 2 trials.

And the best news of all, Insys Therapeutics stock is about to receive another major catalyst on Tuesday, Aug. 1. This catalyst could cause Insys stock to skyrocket, potentially bringing gains of more than 100%...

Buy Insys Therapeutics Stock Before August 1 for Maximum Profits

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Insys Therapeutics is set to bring Syndros to market in August. But the product label treatments for the drug could be just the beginning for it.

Syndros is set to take advantage of two popular trends: medical marijuana and the move away from opioid pain medications in the United States.

The active ingredient in Syndros, Marinol, has been shown effective in treating pain, which potentially creates a large "off-label" market (use of a drug for other purposes than FDA-approved treatments that it has been shown effective to treat) for the drug, according to Patalon. According to Transparency Market Research, the global sales for pain therapeutics is set to grow from $60.2 billion in 2015 to $83 billion by 2024.

Combining the FDA-approved treatments of Syndros with the "off-label" treatments, the market for it is potentially worth billions. Analysts' consensus one-year price target of Insys is $26.00, which represents a potential gain of 112% from today's price.

To maximize your profits, make sure to buy the stock before Aug. 1, when news of the eminent release of the new drug could start driving the stock price much higher than the current price of $12.28 per share.

Start Making More Money Now: Get stock picks and research that could put an extra $125,000 in your pocket delivered straight to your inbox for just pennies a day. Read more...

Follow Money Morning on Twitter @moneymorningFacebook, and LinkedIn.